21st International AIDS Conference (AIDS 2016)


Dolutegravir Superior in Women-Only Study

July 27, 2016

On behalf of IFARA, Fred Schaich spoke with Kimberly Smith, M.D., M.P.H., of ViiV Healthcare about 48-week data from the ARIA study announced at AIDS 2016. The results showed that a fixed-dose combination of dolutegravir/abacavir/lamivudine (Triumeq) was superior to a combination of atazanavir (Reyataz), ritonavir (Norvir) and tenofovir disproxil fumarate/emtricitabine (Truvada) in women who live with HIV. The better outcome in this open-label phase-3b study of 495 participants worldwide was mainly due to lower rates of discontinuation and virological failure in the dolutegravir/abacavir/lamivudine arm.

As people living with HIV become older, well-tolerated, effective antiretroviral regimens with fewer side effects that are easy to use become ever more important, according to Smith. To that end, her company is working on a two-drug combination of dolutegravir (Tivicay, DTG) and rilpivirine (Edurant). Enrollment in clinical trials for that medication has met internal goals of at least 20% of participants being female and at least a quarter being 50 years old or older. Other areas where dolutegravir could be helpful are among those who are coinfected with tuberculosis -- which is particularly relevant in Sub-Saharan Africa, as a second-line treatment and in pediatric HIV, Smith concluded.

Watch the video to learn more:

About the panelist:

  • Kimberly Y. Smith, M.D., M.P.H., ViiV Healthcare

The video above has been posted on with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.

Barbara Jungwirth is a freelance writer and translator based in New York.

Follow Barbara on Twitter: @reliabletran.

Copyright © 2016 Remedy Health Media, LLC. All rights reserved.

Related Stories

Dolutegravir and the Fetus
A Successful Pregnancy and Birth Outcome With Dolutegravir-Based Therapy
Really Rapid Review -- AIDS 2016, Durban

This article was provided by TheBodyPRO. It is a part of the publication The 21st International AIDS Conference (AIDS 2016).

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.